{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002550","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.282499+00:00","generated_at":"2026-06-02T22:42:14.350557+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCryst Q1 ORLADEYO revenue $88.9M (+30% YoY); 2024 guidance raised to $390-$400M","bullets":["Q1 net loss narrowed to $35.4M ($0.17/sh) from $53.3M ($0.28/sh) a year ago.","ORLADEYO net revenue grew 30% YoY to $88.9M; full-year guidance raised to $390-$400M (top end of prior range).","Pipeline: BCX17725 (Netherton syndrome) enters clinic by end 2024; avoralstat (DME) trial planned for 2025.","Pediatric HAE trial (APeX-P) enrollment complete; filing for label expansion to children age 2+ expected in 2025.","Cash and investments $338.4M at Mar 31; net cash use Q1 $52.4M, expects ending 2024 cash above $300M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002550","json":"https://secwatch.observer/filing/0001171843-24-002550.json","markdown":"https://secwatch.observer/filing/0001171843-24-002550.md","text":"https://secwatch.observer/filing/0001171843-24-002550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/0001171843-24-002550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/f8k_050624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:42:14.350557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c60760b05fe1ca936df6ecaee7a88c615a54cd1","claim":"BIOCRYST PHARMACEUTICALS INC reported the first quarter ended March 31, 2024 results: revenue $92.8 million, net income $35.4 million, EPS $0.17 per share. Guidance raised.","evidence_excerpt":"said Dr. Helen Thackray, chief research and development officer of BioCryst. First Quarter 2024 Financial Results For the three months ended March 31, 2024, total revenues were $92.8 million, compared to $68.8 million in the first quarter of 2023 (+34.9 percent y-o-y). The increase was primarily due to $88.9 million in ORLADEYO net revenue in the first quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184324002550/0001171843-24-002550-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$92.8 million"},{"label":"Net income","value":"$35.4 million"},{"label":"EPS","value":"$0.17 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}